A serum-based four-circulating-miR signature (miR-940, miR-451a, miR-15-5p, and miR-17-3p) is predictive of the response to first-line trastuzumab in metastatic HER2-positive breast cancer patients (43). The gene discussed is ERBB2; the disease is breast carcinoma.